A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept

Rheumatology International

Volumn 34, Issue 3, 2014, Pages 443-444

  Akgül, Özgür ^a   Kiliç, Gamze ^a   Kiliç, Erkan ^a   Cüce, Isa ^a   Özgöçmen, Salih ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; INDOMETACIN; INFLIXIMAB; PREDNISOLONE;

ADULT; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; ARTHRITIS; BACKACHE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CASE REPORT; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FEVER; HUMAN; JOINT SWELLING; LETTER; LUPUS LIKE SYNDROME; METACARPOPHALANGEAL JOINT; MORNING STIFFNESS; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; REMISSION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84896736205     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2617-8     Document Type: Letter

References (12)

1. Diaz JC, Vallejo S, Canas CA (2012) Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Rheumatol Int 32(10):3315-3317
2. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J et al (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62(5):1290-1297
3. Kiltz U, Heldmann F, Baraliakos X, Braun J (2012) Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol 24(3):252-260
4. Heldmann F, Dybowski F, Saracbasi-Zender E, Fendler C, Braun J (2010) Update on biologic therapy in the management of axial spondyloarthritis. Curr Rheumatol Rep 12(5):325-331
5. Costa MF, Said NR, Zimmermann B (2008) Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37(6):381-387
6. Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A (2005) Drug-induced lupus erythematosus. Autoimmunity 38(7):507-518
7. Williams EL, Gadola S, Edwards CJ (2009) Anti-TNF-induced lupus. Rheumatology (Oxford) 48(7):716-720
8. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C et al (2005) Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7(3):R545-R551
9. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4):242-251
10. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y et al (2008) TNF alpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 126(1):13-30
11. Subramanian S, Yajnik V, Sands BE, Cullen G, Korzenik JR (2011) Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 17(1):99-104
12. van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA (2006) Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford) 45(10):1317-1319